Efavirenz + 2 NRTIs — Competitive Intelligence Brief

Efavirenz + 2 NRTIs (Efavirenz + 2 NRTIs) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NNRTI + 2 NRTIs). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NNRTI + 2 NRTIs) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Efavirenz + 2 NRTIs (Efavirenz + 2 NRTIs) — National Institute of Allergy and Infectious Diseases (NIAID). Efavirenz inhibits HIV reverse transcriptase while the two NRTIs (nucleoside reverse transcriptase inhibitors) act as chain terminators to block viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Efavirenz + 2 NRTIs TARGET	Efavirenz + 2 NRTIs	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Antiretroviral combination therapy (NNRTI + 2 NRTIs)	HIV reverse transcriptase
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Lamiduvine (Epivir)	Lamiduvine (Epivir)	Catholic University of the Sacred Heart	marketed	Nucleoside Reverse Transcriptase Inhibitor (NRTI)	HIV reverse transcriptase
Abacavir/Lamivudine	Abacavir/Lamivudine	GlaxoSmithKline	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NNRTI + 2 NRTIs) class)

1. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 drug in this class
2. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
4. ViiV Healthcare · 1 drug in this class